These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23802855)

  • 1. Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single centre.
    Aznar JA; García-Dasí M; Pérez-Alenda S; Marco A; Jaca M; Moret A; Querol F
    Vox Sang; 2014 Jan; 106(1):68-74. PubMed ID: 23802855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
    Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
    Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
    Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
    J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
    Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequences of switching from prophylactic treatment to on-demand treatment in late teens and early adults with severe haemophilia A: the TEEN/TWEN study.
    Manco-Johnson MJ; Sanders J; Ewing N; Rodriguez N; Tarantino M; Humphries T;
    Haemophilia; 2013 Sep; 19(5):727-35. PubMed ID: 23750875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome in moderate haemophilia.
    den Uijl I; Biesma D; Grobbee D; Fischer K
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s330-6. PubMed ID: 23245711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
    Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
    Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
    Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
    J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
    Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
    Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
    Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
    Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
    Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
    Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment.
    Wu R; Sun J; Xiao J; Liu Y; Xue F; Wang H; Tang L; Zhao Y; Li K; Yang R; Hu Y; Luke KH; Poon MC; Blanchette VS; Usuba K; Young NL
    Haemophilia; 2017 May; 23(3):430-436. PubMed ID: 28345299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
    Stasyshyn O; Antunes S; Mamonov V; Ye X; Epstein J; Xiong Y; Tangada S
    Haemophilia; 2014 Sep; 20(5):644-50. PubMed ID: 24589084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A.
    Fischer K; Lewandowski D; Janssen MP
    Haemophilia; 2016 Sep; 22(5):e375-82. PubMed ID: 27353496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials.
    Oladapo AO; Epstein JD; Williams E; Ito D; Gringeri A; Valentino LA
    Haemophilia; 2015 Sep; 21(5):e344-58. PubMed ID: 26390060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary prophylaxis in an adult patient with severe haemophilia A. Factor VIII consumption and effectiveness.
    Schlenkrich S; Schubert C
    Hamostaseologie; 2013 Aug; 33(3):241-4. PubMed ID: 23435748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
    Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS
    Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
    Fischer K; Collins P; Björkman S; Blanchette V; Oh M; Fritsch S; Schroth P; Spotts G; Ewenstein B
    Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.